Get the Stockscreener App
0.9101
14.94%
-0.1599
Novabay Pharmaceuticals Inc stock is traded at $0.9101, with a volume of 1.64M.
It is down -14.94% in the last 24 hours and up +41.96% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$1.07
Open:
$1.01
24h Volume:
1.64M
Relative Volume:
0.74
Market Cap:
$5.29M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.1252
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
+47.38%
1M Performance:
+41.96%
6M Performance:
+44.46%
1Y Performance:
+80.63%
1-Day Range:
$0.9101
$1.10
1-Week Range:
$0.586
$1.25
52-Week Range:
$0.44
$1.25
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.9101 | 3.62M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
NovaBay Stock Is Trading Higher Wednesday: What's Going On?NovaBay Pharmaceuticals (AMEX:NBY) - Benzinga
Novabay's 67.5% Surge: A Lifeline Investment Ignites Biotech Drama - AInvest
NovaBay’s Rise: Future Growth or Bubble? - StocksToTrade
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Combining machine learning predictions for NovaBay Pharmaceuticals Inc.July 2025 Breakouts & Capital Protection Trading Alerts - Newser
NovaBay Stock Soars 65.67% on $6M Investment - AInvest
NovaBay Pharmaceuticals Soars 66% In Pre-Market On $6 Million Investment Deal, CEO Appointment - Benzinga
NovaBay Pharmaceuticals shares rise 81.67% premarket after entering a $6 million securities purchase agreement with David E. Lazar. - AInvest
Can volume confirm reversal in NovaBay Pharmaceuticals Inc.Trade Analysis Report & Low Drawdown Investment Strategies - Newser
Historical volatility pattern of NovaBay Pharmaceuticals Inc. visualized2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
NovaBay Pharmaceuticals Secures $6M Investment from David Lazar through Securities Purchase Agreement - AInvest
Price action breakdown for NovaBay Pharmaceuticals Inc.Swing Trade & High Conviction Investment Ideas - Newser
Is NovaBay Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Market Mood & Advanced Technical Analysis Signals - Newser
NovaBay's $6M Lazar Transaction and Strategic Turnaround Potential: A Deep Dive into Capital Restructuring and Shareholder Value Creation in Distressed Biotech Plays - AInvest
NovaBay's Strategic Turnaround: A $6M Lifeline and Leadership Shift Signal New Value Propositions - AInvest
NovaBay jumps after $6 million investment, new CEO - TradingView
NovaBay Pharma Appoints New CEO Amid Strategic Shift - TipRanks
NovaBay Pharmaceuticals enters into $6 million securities purchase agreement with investor David Lazar - MarketScreener
NovaBay Pharmaceuticals Raises $6 Million, Appoints David Lazar CEO. - AInvest
NovaBay Pharmaceuticals Secures $6 Million Investment from David E. Lazar, Appoints New CEO - AInvest
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - FinancialContent
When is the best time to buy NovaBay Pharmaceuticals Inc. stockQuarterly Portfolio Review & High Return Trade Guides - Newser
Screener Results Flag NovaBay Pharmaceuticals Inc. as Oversold2025 Major Catalysts & Safe Entry Momentum Tips - sundaytimes.kr
Can technical indicators confirm NovaBay Pharmaceuticals Inc.’s reversalChart Signals & Safe Entry Momentum Tips - Newser
What’s next for NovaBay Pharmaceuticals Inc. stock price2025 Sector Review & Safe Investment Capital Preservation Plans - Newser
Can NovaBay Pharmaceuticals Inc. rally from current levelsTrade Exit Report & Weekly Stock Breakout Alerts - Newser
Using data tools to time your NovaBay Pharmaceuticals Inc. exitGap Up & Growth Focused Stock Reports - Newser
Is NovaBay Pharmaceuticals Inc. trending in predictive chart modelsWatch List & Weekly Momentum Picks - Newser
Multi asset correlation models including NovaBay Pharmaceuticals Inc.Weekly Loss Report & Free Weekly Chart Analysis and Trade Guides - Newser
Signal strength of NovaBay Pharmaceuticals Inc. stock in tech scannersWeekly Trade Review & Free Fast Entry Momentum Trade Alerts - Newser
Should you wait for a breakout in NovaBay Pharmaceuticals Inc.Portfolio Update Summary & Entry Point Strategy Guides - Newser
What candlestick patterns are forming on NovaBay Pharmaceuticals Inc.Weekly Investment Report & Weekly Stock Performance Updates - Newser
Using Ichimoku Cloud for NovaBay Pharmaceuticals Inc. technicals2025 Volume Leaders & Growth Focused Entry Reports - Newser
Custom watchlist performance reports with NovaBay Pharmaceuticals Inc.Quarterly Growth Report & Community Driven Trade Alerts - Newser
Why NovaBay Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Institutional & Fast Gain Stock Tips - 선데이타임즈
Analyzing recovery setups for NovaBay Pharmaceuticals Inc. investors2025 Market Overview & Precise Buy Zone Tips - Newser
How to manage a losing position in NovaBay Pharmaceuticals Inc.Dip Buying & Free Weekly Watchlist of Top Performers - Newser
Is now a turning point for NovaBay Pharmaceuticals Inc.Analyst Upgrade & Accurate Intraday Trade Tips - Newser
Using Bollinger Bands to evaluate NovaBay Pharmaceuticals Inc.July 2025 Spike Watch & Real-Time Chart Breakout Alerts - Newser
How hedge fund analytics apply to NovaBay Pharmaceuticals Inc. stockJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
News impact scoring models applied to NovaBay Pharmaceuticals Inc.July 2025 Earnings & AI Enhanced Market Trend Forecasts - Newser
Published on: 2025-08-15 17:57:23 - Newser
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):